Below are the most recent publications written about "Dabigatran" by people in Profiles.
-
Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Kasab SA, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, El Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Leon Guerrero CR, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke. 2022 03; 53(3):728-738.
-
Singh S, Nautiyal A, Belk KW. Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study. Am J Cardiovasc Drugs. 2020 Apr; 20(2):161-168.
-
Alcusky M, Hume AL, Fisher M, Tjia J, Goldberg RJ, McManus DD, Lapane KL. Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities. Drugs Aging. 2018 12; 35(12):1089-1098.
-
Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017 12; 117(12):2415-2424.
-
Tang W, Chang HY, Zhou M, Singh S. Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis. Sci Rep. 2017 01 20; 7:40120.
-
Yogaratnam D, Ditch K, Medeiros K, Doyno C, Fong JJ. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation. Ann Pharmacother. 2016 10; 50(10):847-54.
-
Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD. Perioperative Management of Dabigatran: A Prospective Cohort Study. Circulation. 2015 Jul 21; 132(3):167-73.
-
Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015 Apr 24; 350:h1585.
-
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015 Apr 24; 350:h1857.
-
Rollins BM, Silva MA, Donovan JL, Kanaan AO. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. Clin Ther. 2014 Oct 01; 36(10):1454-64.e3.